和中止鼽方配合穴位注射治疗肺脾气虚型变应性鼻炎的临床疗效

发布时间：2018-06-03 11:49

  本文选题：和中止鼽方 + 穴位注射　； 参考：《西南医科大学》2016年硕士论文

【摘要】：目的:探讨和中止鼽方配合穴位注射治疗肺脾气虚型变应性鼻炎(Allergic rhinitis,AR)的临床疗效,为和中止鼽方配合穴位注射疗法在临床应用推广提供支撑依据。方法:采用两个中心(西南医科大学附属中医医院及重庆市垫江县中医院)随机对照试验方法,本研究所纳入的患者均为2015年8月至2016年1月就诊的AR患者,应用口服和中止鼽方汤剂配合穴位注射的方法治疗,并与应用口服氯雷他定分散片配合布地奈德鼻用气雾剂喷鼻相比较,依照纳入与排除标准,共收集了临床确诊的肺脾气虚型AR52例有效病例,其中治疗组26例,口服和中止鼽方汤剂,每次量200ml,每日1剂,连服7日,隔7日后再服7日,同时行双侧迎香穴穴位注射,每周1次,3周为一个疗程;对照组26例采用口服氯雷他定分散片,每晚一片,连服14日,同时使用布地奈德鼻用气雾剂喷鼻,早晚各一次,3周为一个疗程。治疗结束后门诊随访4周。在患者治疗前、治疗结束后1周及治疗结束后4周进行视觉模拟评分量表(visual analogue scale,VAS)评分、鼻眼结膜相关生活质量问卷调查量表(Rhinocoujunctivitis Quality of Life Questionaire)(中文版自测版本)评分以及鼻内镜检查评分,通过比较评估临床疗效。结果:1、治疗前两组患者VAS、RQLQ积分比较无差异,P0.05;完成治疗后1周,治疗组患者VAS、RQLQ积分明显低于对照组,P0.05;完成治疗4周后,治疗组患者VAS、RQLQ积分明显低于对照组,P0.05。2、在治疗前,两组患者单项症状VAS评分及鼻部体征比较无明显差异,P0.05;完成治疗一周后,治疗组患者在鼻塞、喷嚏和鼻部体征的比较中积分低于对照组,P0.05;在完成治疗4周后,治疗组患者鼻塞、鼻痒、喷嚏、流体等鼻部症状及鼻部体征均积分均明显低于对照组,P0.05。3、治疗组患者显效12例(48.0%),有效12例(48.0%),无效1例(4.0%),总有效24例,总有效率为96.0%。对照组患者显效8例(33.3%),有效7例(29.2%),无效9例(37.5%),总有效15例,总有效率为62.5%,P0.05。结论:和中止鼽方配合穴位注射治疗可以提高肺脾气虚型AR患者的临床治疗有效率,同时也可以有效改善AR患者的临床症状,提升患者生活质量。
[Abstract]:Objective: to investigate the clinical effect of Qiu prescription combined with acupoint injection in the treatment of allergic rhinitis ARA with asthenia of lung and spleen qi, and to provide the support basis for the clinical application and popularization of Qiu prescription and acupoint injection therapy. Methods: two centers (affiliated traditional Chinese Medicine Hospital of Southwest Medical University and Chongqing Dianjiang traditional Chinese Medicine Hospital) were used in the randomized controlled trial. The patients included in the study were AR patients from August 2015 to January 2016. Oral and stop Qiu decoction combined with acupoint injection were used, and compared with oral loratadine dispersible tablets combined with budesonide nasal aerosol spray, according to the inclusion and exclusion criteria, A total of effective cases of lung and spleen qi deficiency type AR52 were collected. In the treatment group, 26 cases were treated by oral administration and Xiaoqifang decoction at a dose of 200 ml, 1 dose per day for 7 days, and 7 days after taking, at the same time, the treatment group was given bilateral Yingxiang acupoint injection. 26 patients in the control group were treated with oral loratadine dispersible tablets once a night for 14 days, and budesonide nasal spray with aerosol in the morning and evening. The patients were followed up for 4 weeks after treatment. Visual analogue scale (VAS) was performed before treatment, 1 week after treatment and 4 weeks after treatment. The Rhinocoujunctivitis Quality of Life questionnaire scale (Rhinocoujunctivitis Quality of Life questionnaire) and the nasal Endoscopy scale (ESS) were used to evaluate the clinical efficacy. Results there was no significant difference in the RQLQ scores between the two groups before and after treatment (P0.05). The RQLQ scores of the patients in the treatment group were significantly lower than those in the control group (P0.05) one week after the completion of treatment. After 4 weeks of treatment, the RQLQ scores of the patients in the treatment group were significantly lower than those in the control group (P0.05.2), and before the treatment, the RQLQ scores of the patients in the treatment group were significantly lower than those in the control group (P < 0.05). There was no significant difference in single symptom VAS score and nasal signs between the two groups (P 0.05). After one week of treatment, the scores of nasal congestion, sneezing and nasal signs in the treatment group were lower than those in the control group (P 0.05); after 4 weeks of treatment, the nasal obstruction in the treatment group was lower than that in the control group. The scores of nasal symptoms, symptoms and signs of nasal itch, sneeze and fluid were significantly lower than those of control group (P 0.05.3). In the treatment group, 12 cases had remarkable effect (48.0%), 12 cases had effective measures (48.0%), 1 case had no effect (4.0%), 24 cases were effective, and the total effective rate was 96.0 鈩，

本文编号：1972674